BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 9933801)

  • 1. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
    Del Nero A; Esposito N; Currò A; Biasoni D; Montanari E; Mangiarotti B; Trinchieri A; Zanetti G; Serrago MP; Pisani E
    Eur Urol; 1999 Feb; 35(2):93-7. PubMed ID: 9933801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
    Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
    Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
    BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
    Wiener HG; Mian C; Haitel A; Pycha A; Schatzl G; Marberger M
    J Urol; 1998 Jun; 159(6):1876-80. PubMed ID: 9598479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.
    Friedrich MG; Hellstern A; Hautmann SH; Graefen M; Conrad S; Huland E; Huland H
    J Urol; 2002 Aug; 168(2):470-4. PubMed ID: 12131290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study.
    Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juárez FM; Martín García B
    Urol Int; 2001; 66(4):185-90. PubMed ID: 11385303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMP22 in transitional cell carcinoma of the urinary bladder.
    Su CK; Yang CR; Horng YY; Kao YL; Ho HC; Ou YC; Cheng CL
    J Chin Med Assoc; 2003 May; 66(5):294-8. PubMed ID: 12908572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat.
    Sharma S; Zippe CD; Pandrangi L; Nelson D; Agarwal A
    J Urol; 1999 Jul; 162(1):53-7. PubMed ID: 10379739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM; Kiemeney LA; Witjes JA
    Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder.
    Serretta V; Pomara G; Rizzo I; Esposito E
    Eur Urol; 2000 Oct; 38(4):419-25. PubMed ID: 11025380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder.
    Chahal R; Darshane A; Browning AJ; Sundaram SK
    Eur Urol; 2001 Oct; 40(4):415-20; discussion 421. PubMed ID: 11713396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
    Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
    Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary dosage of nuclear matrix protein 22 (NMP22) like biologic marker of transitional cell carcinoma (TCC): a study on patients with hematuria.
    Paoluzzi M; Cuttano MG; Mugnaini P; Salsano F; Giannotti P
    Arch Ital Urol Androl; 1999 Feb; 71(1):13-8. PubMed ID: 10193018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.
    Kundal VK; Pandith AA; Hamid A; Shah A; Kundal R; Wani SM
    Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.
    Stampfer DS; Carpinito GA; Rodriguez-Villanueva J; Willsey LW; Dinney CP; Grossman HB; Fritsche HA; McDougal WS
    J Urol; 1998 Feb; 159(2):394-8. PubMed ID: 9649246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
    Shariat SF; Casella R; Monoski MA; Sulser T; Gasser TC; Lerner SP
    J Urol; 2003 Dec; 170(6 Pt 1):2244-7. PubMed ID: 14634389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.